Adiponectin – Its Potential to Predict and Prevent Coronary Artery Disease

Abstract

Background: Recent evidence suggests that epicardial adipose tissue may contribute locally to the pathogenesis of coronary artery disease (CAD). We investigated how local and systemic adiponectin, an adipokine with anti-inflammatory and insulin sensitizing properties, is related to the presence of CAD and cardiovascular risk factors. Methods: Serum and adipose tissue samples from subcutaneous and pericoronary depots were collected from sixty consecutive patients with CAD who required coronary artery bypass grafting or patients without CAD who underwent cardiac surgery for aortic valve replacement. Western blot, ELISA and PCR were used to detect and determine the adiponectin concentrations and expression in the samples. Results: Adiponectin concentrations in the serum and pericoronary fat of patients without CAD were significantly higher than in patients with CAD (p < 0.01). However, the expression of adiponectin mRNA did not differ in any instances. Male gender, BMI > 30 and type 2 diabetes were significantly correlated to decreased serum adiponectin (p < 0.03). Conclusion: Pericoronary fat specifically secretes metabolically active adiponectin. Its local and systemic concentrations are inversely correlated to the presence of coronary artery disease, indicating its anti-atherogenic effects. As for patients with CAD, adiponectin might be a promising marker for intra-individual monitoring of cardiovascular risk factors and thus a course of secondary prevention. Further evaluation is necessary to elucidate whether a novel therapeutic option could be derived against the onset and progression of CAD.

cardiovascular surgery - coronary bypass surgery - heart valve surgery

References

• 1 Mazurek T, Zhang L, Zalewski A et al. Human epicardial adipose tissue is a source of inflammatory mediators.  Circulation. 2003;  108 2460-2466
• 2 Henrichot E, Juge-Aubry C E, Pernin A et al. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis?.  Arterioscler Thromb Vasc Biol. 2005;  25 2594-2599
• 3 Hansson G K. Inflammation, atherosclerosis, and coronary artery disease.  N Engl J Med. 2005;  352 1685-1695
• 4 Gesta S, Bluher M, Yamamoto Y et al. Evidence for a role of developmental genes in the origin of obesity and body fat distribution.  Proc Natl Acad Sci USA. 2006;  103 6676-6681
• 5 Tchkonia T, Lenburg M, Thomou T et al. Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns.  Am J Physiol Endocrinol Metab. 2007;  292 E298-E307
• 6 Combs T P, Berg A H, Obici S, Scherer P E, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30.  J Clin Invest. 2001;  108 1875-1881
• 7 Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.  Biochem Biophys Res Commun. 1999;  257 79-83
• 8 Okamoto Y, Kihara S, Ouchi N et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice.  Circulation. 2002;  106 2767-2770
• 9 Goldstein B J, Scalia R G, Ma X L. Protective vascular and myocardial effects of adiponectin.  Nat Clin Pract Cardiovasc Med. 2009;  6 27-35
• 10 Iacobellis G, di Gioia C R, Cotesta D et al. Epicardial adipose tissue adiponectin expression is related to intracoronary adiponectin levels.  Horm Metab Res. 2009;  41 227-231
• 11 Scherer P E, Williams S, Fogliano M, Baldini G, Lodish H F. A novel serum protein similar to C1 q, produced exclusively in adipocytes.  J Biol Chem. 1995;  270 26746-26749
• 12 Ouchi N, Kihara S, Arita Y et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway.  Circulation. 2000;  102 1296-1301
• 13 Ibrahim M M. Subcutaneous and visceral adipose tissue: structural and functional differences.  Obes Rev. 2009;  11 11-18
• 14 Joe A W, Yi L, Even Y, Vogl A W, Rossi F M. Depot-specific differences in adipogenic progenitor abundance and proliferative response to high fat diet.  Stem Cells. 2009;  27 2563-2570
• 15 Chatterjee T K, Stoll L L, Denning G M et al. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding.  Circ Res. 2009;  104 541-549
• 16 Wilkie G S, Dickson K S, Gray N K. Regulation of mRNA translation by 5′- and 3′-UTR-binding factors.  Trends Biochem Sci. 2003;  28 182-188
• 17 Banga A, Unal R, Tripathi P et al. Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids.  Am J Physiol Endocrinol Metab. 2009;  296 E480-E489
• 18 Lindsay R S, Funahashi T, Hanson R L et al. Adiponectin and development of type 2 diabetes in the Pima Indian population.  Lancet. 2002;  360 57-58
• 19 Tsunekawa T, Hayashi T, Suzuki Y et al. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects.  Diabetes Care. 2003;  26 285-289
• 20 Brody R, Peleg E, Grossman E, Sharabi Y. Production and secretion of adiponectin from 3T3-L1 adipocytes: comparison of antihypertensive drugs.  Am J Hypertens. 2009;  22 1126-1129
• 21 Nakamura T, Kawachi K, Saito Y et al. Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension.  Int Heart J. 2009;  50 501-512
• 22 Piecha G, Adamczak M, Chudek J, Wiecek A. Indapamide decreases plasma adiponectin concentration in patients with essential hypertension.  Kidney Blood Press Res. 2007;  30 187-194
• 23 Poyhonen-Alho M K, Manhem K, Katzman P et al. Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women.  J Hypertens. 2008;  26 2445-2449
• 24 Valsamakis G, McTernan P G, Chetty R et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.  Metabolism. 2004;  53 430-434
• 25 Hulver M W, Zheng D, Tanner C J et al. Adiponectin is not altered with exercise training despite enhanced insulin action.  Am J Physiol Endocrinol Metab. 2002;  283 E861-E865